Skip to main content
News

Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding DPYD Testing

By January 31, 2025December 24th, 2025No Comments

Houda Hachad, PharmD, M.Res, was interviewed by the Journal of Clinical Pathways to discuss recommendations for standardizing DPYD pharmacogenomic testing.

The impact of Fluoropyrimidines-induced severe toxicity can no longer be overlooked. Preemptive genetic testing for DPYD pathogenic variants must become standard practice to identify at-risk patients and prevent life-threatening complications, positioning DPYD testing as a public health priority. – Houda Hachad, VP of Clinical Operations at Aranscia

Click here to watch “Recommendations for Standardizing DPYD Pharmacogenomic Testing” – an interview between Houda Hachad and the Journal of Clinical Pathways.

Leave a Reply